As they are approaching the third phase, ADCETRIS has had much progress in being turned into a major franchise. This is allowing new methods of treatments to be used for patients and will support future label expansions. Clinical trials will help to speed up the recovery rate of many AML patients.
Total revenues for Seattle Genetics, Inc. in the second quarter included $95.4 million and sales of $66.2 million. This is up twenty percent from previous reports from one year ago.
Clay Siegall is committed to finding treatment options for different types of cancers. He is President and Chief Executive Officer for Seattle Genetics, Inc.. He also holds the seat of Chairman of the Board for Seattle Genetics, Inc. He also joined the board for Ultragenyx in 2014. He is associated with many other medical companies as well.
Seattle Genetics, Inc. has done a lot of research and development in different types of medications and other therapeutic treatment options. They do a lot of clinical trials with patients that will allow them to also. Siegall supports everything that the company does and wants to improve the services that are offered to patients who are fighting horrible diseases, such as cancer.
There are often unmet medical needs that each patient faces when they are fighting cancer. Siegall has come up with a plan to help address these situations.
Coming up with a new treatment for people who are suffering from a deadly disease offers new hope for them and their families. Seattle Genetics, Inc. is doing just that. They are offering more treatment options, including therapeutic options that are available. Every patient deserves to be offered that ray of hope during this very difficult time in their life.